Wolwo Pharma(SZ:300357) Xin Lang Cai Jing·2025-10-23 01:29Core Viewpoint - Iwubio experienced a decline of 3.18% in stock price on October 22, with a trading volume of 323 million yuan, indicating potential market volatility and investor sentiment shifts [1] Financing Summary - On October 22, Iwubio had a financing buy-in amount of 38.93 million yuan and a financing repayment of 53.99 million yuan, resulting in a net financing outflow of 15.07 million yuan [1] - The total financing and securities lending balance for Iwubio reached 430 million yuan, with the financing balance accounting for 2.58% of the circulating market value, indicating a high level of financing activity compared to the past year [1] - The company had a securities lending repayment of 2,100 shares and a securities lending sell-out of 1,100 shares, with a sell-out amount of 34,800 yuan calculated at the closing price [1] Business Performance - As of June 30, Iwubio reported a total of 34,600 shareholders, a decrease of 3.53% from the previous period, while the average circulating shares per person increased by 3.66% to 13,999 shares [2] - For the first half of 2025, Iwubio achieved an operating income of 484 million yuan, representing a year-on-year growth of 12.81%, and a net profit attributable to shareholders of 177 million yuan, up 18.61% year-on-year [2] Dividend and Shareholding Information - Since its A-share listing, Iwubio has distributed a total of 913 million yuan in dividends, with 317 million yuan distributed over the past three years [3] - As of June 30, 2025, among the top ten circulating shareholders, the China National Securities Bio-Medical Index A (161726) held 4.69 million shares, a decrease of 188,000 shares from the previous period, while Hong Kong Central Clearing Limited held 4.11 million shares, down 491,800 shares [3]